Christmas is almost here, and we hope you, like all of us in the I.H.S. office, are getting excited for the fun and festivities ahead! Our Winter Magazine is out now and you should all have received a copy in the post , but if you would like to read the digital version, you can …
Agreement has been reached on the continued provision of Extended Half Life (EHL) FVIII as an option for the treatment of Haemophilia A in Ireland for a further year to the end of 2020. The Haemophilia Product Selection and Monitoring Advisory Board (HPSMAB) have extended the contract for the supply of recombinant extended half- life …
Emicizumab (brand name: Hemlibra) is a bi-specific antibody which binds to both activated FIX and FX and allows the coagulation cascade to continue, and the blood to clot, in the absence of FVIII. Hemlibra mimics the effect of FVIII and can be used as an option for prophylaxis for people with FVIII deficiency. Hemlibra has …
New Treatment Option for Prophylaxis in Severe Haemophilia A Read More »
The Patient Advocacy Service is a new independent, free and confidential service to assist people to make a complaint about the care they have experienced in public acute hospitals. Funded directly by the Department of Health and developed by The National Advocacy Service for People with Disabilities this new service is for all patients of …
New Independent Patient Advocacy Service Launched Read More »
